{
  "report_rows": [
    {
      "kpi": "Organic Req. Volume Growth (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~8.5% vs. cons 7.8%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue per Requisition (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$44.20 vs. cons $44.36",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. Diluted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$2.87 vs. cons $2.836",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY Revenue (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$11.94B midpoint vs. cons $11.850B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY Adj. EPS (FY 2026)",
      "prediction": "BETTER",
      "answer": "guide ~$10.85 midpoint vs. cons $10.766",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "ACA impact commentary (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "Confirm 30bp assumption, no deterioration",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 5.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.0,
  "day5_path": "FADE",
  "day5_rationale": "FADE \u2014 initial pop partially given back as modest FY raise drives small estimate revisions; no squeeze amplifier; stock stabilizes above day-0 open",
  "day5_confidence": "MEDIUM"
}